NCT02671799Unknown不适用
Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR): First-In-Man Continuation Study
Mardil Medical4 个研究点 分布在 2 个国家目标入组 15 人开始时间: 2016年1月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 发起方
- 入组人数
- 15
- 试验地点
- 4
- 主要终点
- Evaluate mean reduction in MR, and freedom from grade 3 and 4 MR at 6 months post-therapy adjustment, as measured by an echocardiographic core lab
研究概览
简要总结
This is a prospective, multi-center, single-arm study to evaluate the VenTouch System for treatment of moderate to moderate-severe functional mitral valve regurgitation [FMR].
详细描述
This trial is a prospective, multi-center, single-arm First-In-Man Continuation study to evaluate safety and efficacy of the VenTouch System for treatment of subjects with functional MR enrolling up to 15 subjects who have been diagnosed with Grade 3-4 functional mitral valve regurgitation. The duration of the study follow-up is 36 months from the time of therapy adjustment. Data from this trial may be utilized in support of a CE study in Europe and/or a pilot IDE study in the U.S. Follow-up testing will be performed at 1 month, 3 months, 6 months, and 12, 24, and 36 months post-therapy adjustment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults ≥18 years of age
- •Symptomatic FMR of grade moderately severe to severe (3 to 4) with structurally normal leaflets (preferably with echocardiographic evidence of EROA> 0.20 cm2)
- •NYHA Class II to IV
- •Left Ventricular Ejection Fraction (LVEF) 20%-50%
- •Treatment with optimal guideline-directed medical therapy for heart failure for at least 30 days. Subjects must be receiving a beta blocker for 3 months and an ACE-I or ARB for one month unless, in the investigator's opinion, the subject is intolerant to beta blockers, ACE-I or ARB. Beta blockers and ACE-I (or ARB) doses should be stable for one month prior to study entry. Stable is defined as no more than a 100% increase or a 50% decrease in dose.
- •Subjects with a Class I indication for CRT implant according to current guidelines should have CRT implant prior to entry into the study. Subjects who have existing CRT implants may be included in the study if the implant has been in place for at least 90 days.
- •Left Ventricular End Diastolic Diameter (LVEDD) of 55 to 80 mm as determined by transthoracic echocardiography.
- •Subject is willing and available to return for study follow-up
- •Subject or legal representative understands and provides signed informed consent for participation in study
- •Acceptance of subject for trial enrollment after review of all subject baseline data by Study Selection Committee
排除标准
- •Life expectancy of less than 12 months due to conditions other than cardiac status
- •Identified need for any cardiovascular surgery
- •Untreated clinically significant coronary artery disease
- •Any procedure, condition or cardiac anatomy that may impact or compromise the pericardial space (e.g. prior mitral valve surgery, CABG, epicardial pacing leads, pericarditis, or other procedure involving pericardial access)
- •Percutaneous coronary intervention, acute coronary syndrome (e.g. STEMI or non-STEMI myocardial infarction, unstable angina) or clinically significant cardiac events (e.g hypotension, syncope, arrhythmias, embolism, heart failure exacerbation or any hospitalization) within 30 days of enrollment
- •Thoracic or cardiac surgery contraindication (e.g., acute respiratory distress, endocarditis, myocarditis, pericarditis)
- •Significant structural abnormality of the mitral valve (e.g. flail leaflets, ruptured or elongated chordae, prolapsed valve, perforated valve leaflets, significant calcification in the annulus, or calcification in the leaflets that restricts motion)
- •Severe symptomatic carotid stenosis
- •Severe or sustained pulmonary hypertension, defined by resting pulmonary artery systolic (PAS) pressure greater than or equal to 70 mm Hg
- •Physical evidence of right-sided congestive heart failure with echocardiographic evidence of moderate or severe right ventricular dysfunction
- •Hypotension (systolic pressure <90mm Hg)
- •Hypertrophic cardiomyopathy, restrictive cardiomyopathy, or any other structural heart disease causing heart failure other than dilated cardiomyopathy
- •UNOS status 1 heart transplantation
- •Creatinine > 2.5 mg/dL (221 µmol/L) and/or renal failure requiring dialysis
- •Active systemic infection or bleeding
- •Autoimmune disorders and/or the use of immune suppression therapy
- •Females who are pregnant (as documented by HCG beta pregnancy test in females of child-bearing age) or lactating
- •Currently enrolled in another investigational drug or device study
- •Intra-Operative Exclusion Criteria:
- •Subjects with heart size outside of the offered VenTouch System size range
- •Significant structural abnormality of the mitral valve (e.g. flail leaflets, ruptured or elongated chordae, prolapsed valve, perforated valve leaflets, significant calcification in the annulus, or calcification in the leaflets that restricts motion)
- •Signs/indications of ischemia
- •Intra-operative coronary angiography demonstrates that there is compression of the coronary arteries or reduction in coronary blood flow due to the VenTouch implant
结局指标
主要结局
Evaluate mean reduction in MR, and freedom from grade 3 and 4 MR at 6 months post-therapy adjustment, as measured by an echocardiographic core lab
时间窗: 6 months
Evaluate Serious Adverse Event (SAE) rates at 6 months post-therapy adjustment
时间窗: 6 months
次要结局
- Evaluate mean reduction in MR, and freedom from grade 3 and 4 MR, as demonstrated by quantitative measures, as measured by an echocardiographic core lab(Through 36 Months)
- Evaluate Serious Adverse Event (SAE) rates(Through 36 Months)
- Quantitative assessment of reverse remodeling based on change in LVEDD, LVEF, as measured by an echocardiographic core lab(Through 36 Months)
- Improvement in patient symptoms as assessed by the NYHA functional class(Through 36 Months)
- Improvement in Six-Minute Walk(Through 36 Months)
- Improvement in Minnesota Living with Heart Failure Questionnaire(Through 36 Months)
研究者
研究点 (4)
Loading locations...
相似试验
Unknown
不适用
VenTouch OUS Feasibility StudyFunctional Mitral RegurgitationNCT03616678Mardil Medical15
已完成
不适用
A Study to Test Performance of Needle Placements for Neuraxial Procedures Using Tactile Imaging vs ControlCentral Nervous System InfectionsPseudotumor CerebriNeurological DisorderObstetric Procedure PainOrthopedic Procedure PainPost-Dural Puncture HeadacheCancerNCT04796935IntuiTap Medical, Inc95
已完成
不适用
VIRTUS: An Evaluation of the Vici™ Venous Stent System in Patients With Chronic Iliofemoral Venous Outflow ObstructionChronic Venous DisorderVenous Outflow ObstructionSymptomatic Venous Outflow Obstruction of Iliofemoral VeinNCT02112877Boston Scientific Corporation200
Unknown
不适用
V-Sensors for Vitals: Assessment of the Accuracy of a Vital Sign Sensor Mounted on a SmartphoneClinical Accuracy of Vital Sign Pressure SensorNCT03321851Léman Micro Devices SA95
已完成
不适用
Treatment of Actinic Keratosis With 5% KOH SolutionActinic KeratosesNCT04024579Infectopharm Arzneimittel GmbH73